Payer Evidence · Health Economics · Market Access
Wamukelekile
Welcome, you all the travelers of the world. Uthando Nethemba reads clinical trials and health-policy signals closely — turning them into decision-ready notes on evidence, health economics, and market access.
Latest from the Blog
Metabolic engineering and bioproduction — engineering a pathway to a lab titer is the easy part; commercial-scale $/kg cost-competitiveness is the real bottleneck
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All titer, yield, carbon-cost, $/kg and capex figures are attributed to the specific strain, conditions, techno-economic (TEA) assumptions or announcement they come from; peer-reviewed data, company claims, trade press and TEA models are…
The quantum-sensing landscape — the most mature corner of quantum technology, but genuine “beats-classical-in-the-field” advantage is narrow, not broad
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All sensitivity, stability and precision figures are attributed to the specific instrument, trial or company; peer-reviewed results, company claims and agency projections are labeled and kept separate (noted inline). Sensitivities quoted for different…
The fusion commercialization paradox — the private-capital boom is real (a record $4.48bn in 12 months, $14.24bn cumulative), yet that money has moved zero of the outcome-layer metrics that actually gate grid electricity
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All funding, valuation and roadmap figures are attributed to the industry association, the company, or the primary filing; many are company press releases, SPAC merger figures or association surveys rather than audited or…
Get new content delivered directly to your inbox.
Uthando Nethemba 